However, 11 of 13 evaluableThis translocation results in the chimeric ASPSCR1TF transcription factor which drives tumorigenesis Complete surgical resection is crucial in allowing a successful outcome in these cases Here, we describe an 11monthold female infant who presented with a wellcircumscribed lesion of the tongue, with the clinical and radiologicASPSCR1TF In order to characterize the fusion gene associated with ASPS and its role in sarcomagenesis, we created a novel mouse allele designed to express ASPSCR1TF conditionally Briefly, the Rosa26LSLAT3 allele was generated by isolating the type 2 ASPSCR1TF fusion gene transcript from total RNA obtained from a human ASPS
Www Cell Com Cancer Cell Pdfextended S1535 6108 14 3
Aspscr1-tfe3
Aspscr1-tfe3- Breakpoint for translocation to form NONOTF, PSFTF and ASPSCR1TF oncogenes 2 Keywords Disease i Protooncogene Organismspecific databases DisGeNET i 7030 MalaCards i TF OpenTargets i ENSG Orphanet i , Alveolar soft tissue sarcoma RTPCR was performed to confirm the presence of an ASPSCR1TF and PRCCTF fusion transcript by using forward primers from the ASPSCR1 and PRCC sequence and a reverse primer from TF exon The image result ( Figure 6 ) showed specific ASPSCR1TF and PRCCTF products which confirmed the diagnosis of TF RCC and also identified the
Melanotic subtype generally harbors the SFPQTF fusion and rarely ARID1BTF Plasmid construction Nterminal FLAGtagged ASPSCR1TF was introduced into both the pMYsIRESGFP and pMYsIRESLuc vectors The fulllength ASPSCR1TF was cloned from a human ASPS case Artificial chimeric ASPSCR1 fusions between ASPSCR1 and TFEB, TFEC, or MITF were also generated by twostep PCR using primers encompassing both ASPSCR1 andNo fusionnegative case has ever been described Complete surgical excision, including lung metastasectomy when applicable, is the primary treatment, with limited benefit associated with chemotherapy or radiation There has been one published case of primary ASPS in the bladder
Oncogenic rearrangements of the TF transcription factor gene are found in two distinct human cancers These include ASPSCR1TF in all cases of alveolar soft part sarcoma (ASPS) and ASPSCR1TF, PRCCTF, SFPQTF and others in a subset of paediatric and adult RCCs Here we examined the functi The difference in expression of cathepsin K between the PRCCTF and ASPSCR1TF carcinomas, together with the observed clinical differences between these subtypes of Xp11 translocation The ASPSCR1 TF fusion gene retains the DNA binding and activation domain of TF, whereas the Nterminal region of TF is replaced with ASPSCR1 sequences ASPSCR1 TF is known to upregulate the Met receptor tyrosine kinase gene and induce oncogenic phenotypes such as uncontrolled cell proliferation, invasion, and metastasis
Regional lymph nodes were involved by metastasis in 24 of the 32 ASPSCR1TF cases in which nodes were resected, compared with 5 of 14 PRCCTF cases (P=002);3 ASPSCR1 TEXT A number sign (#) is used with this entry because some cases of alveolar soft part sarcoma have been found to be caused by fusion of the ASPSCR1 () and TF () genes Description Alveolar soft part sarcoma is an unusual tumor with highly characteristic histopathology and ultrastructureTether containing UBX domain for GLUT4 (TUG) is a protein that in humans is encoded by the ASPSCR1 gene This gene is a candidate gene for alveolar soft part sarcoma (ASPS) It has been found that ASPSCR1 can undergo oncogenic rearrangement with transcription factor TF gene, creating an aberrant gene that is a stronger transcriptional activator than TF alone
By conditionally expressing in mice the fusion gene ASPSCR1TF from human alveolar soft part sarcoma (ASPS), we generated a model that recapitulates the human tumor histologically and by expression profile, enabling study of the conditions supportive of tumor development Mouse tumors demonstrated angiogenic gene expression in the frank absence of hypoxia and wereDescription Homo sapiens transcription factor binding to IGHM enhancer 3 (TF), transcript variant 1, mRNA (from RefSeq NM_) RefSeq Summary (NM_) This gene encodes a basic helixloophelix domaincontaining transcription factor that binds MUtype Ebox sequences in the promoter of genes The encoded protein promotes the expression of genesA conditional expression in mice of the fusion gene ASPSCR1TF from human alveolar soft part sarcoma (ASPS) generated a model that recapitulates the human tumor histologically and by expression profile
Note=A chromosomal aberration involving TF is found in patients with alveolar soft part sarcoma Translocation t(X;17)(p11;q25) with ASPSCR1 forms a ASPSCR1TF fusion protein Note=Chromosomal aberrations involving TF are found in The present model also enabled the evaluation of TFE/MITF family transcription factor function, which demonstrated that ASPSCR1TFEB possessed definitive albeit less marked oncogenic activity than that of ASPSCR1TF Collectively, our mouse model provides a tool to understand oncogenic, angiogenic, and metastatic mechanisms of ASPSAims Alveolar soft part sarcoma (ASPS) is a rare soft tissue tumour with unique morphology and a recurrent, nonreciprocal translocation der(17)t(X;17)(p112;q25) leading to the fusion of ASPSCR1 (also known as ASPL) to the transcription factor TF Although diagnosis is straightforward in classical cases, tumours with atypical morphological features may be difficult to classify solely on
Significance By conditionally expressing in mice the fusion gene ASPSCR1TF from human alveolar soft part sarcoma (ASPS), we generated a model that recapitulates the human tumor histologically and by expression profile, enabling study of the conditions supportive of tumor development Mouse tumors demonstrated angiogenic gene expression in the frank absence of The ASPSCR1/TF fusion replaces the Nterminal portion of TF by the fused ASPSCR1 sequences, while retaining the TF DNAbinding domain, implicating transcriptional deregulation in the pathogenesis of ASPS Ladanyi et al (01) identified major and minor splice forms of the ASPSCR1 transcript which differ by the absence or presence of a 47 These include ASPSCR1–TF in all cases of alveolar soft part sarcoma (ASPS) and ASPSCR1–TF, PRCC‐TF, SFPQ‐TF and others in a subset of paediatric and adult RCCs Here we examined the functional properties of the ASPSCR1–TF fusion oncoprotein, defined its target promoters on a genome‐wide basis and performed a high
Alveolar soft part sarcoma (ASPS) is an exceptionally rare nonrhabdomyosarcomatous soft tissue sarcoma (NRSTS), characterized by the translocation t(X;17) p(112;q25) This translocation results in the chimeric ASPSCR1TF transcription factor whichTF is also expressed in alveolar soft part sarcoma the hallmark of which is a chromosomal rearrangement at 17q25 and Xp112 engendering an ASPSCR1–TF fusion gene Use of this antibody is an aid in the recognition of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma within the context of an antibody panelOncogenic rearrangements of the TF transcription factor gene are found in two distinct human cancers These include ASPSCR1–TF in all cases of alveolar soft part sarcoma (ASPS) and ASPSCR1–TF,
A conditional expression in mice of the fusion gene ASPSCR1TF from human alveolar soft part sarcoma (ASPS) generated a model that recapitulates the human tumor histologically and by expression profile ASPL is a cofactor of the hexameric ATPase complex, known as p97 The central area in ASPL, containing both a SHP box and a UBX domain, is The ASPSCR1TF fusion protein acts as an aberrant transcription factor resulting in activation of the MET signaling pathway believed to promote angiogenesis and cell proliferation 2 In a study performed by Tsuji et al, 22 they showed the sensitivity and specificity of TF immunohistochemistry for ASPS to be 92% and 92%, respectively Tfe3 is a critical transcription factor that regulates Pgc1alpha gene expression in myotubes;
TFF Alveolar softpart sarcoma (ASPS) is a rare malignant tumor typically occurring in patients in their s to 30s within the muscle and deep tissues of the extremities ASPS is slow growing and refractory to chemotherapy with a propensity to metastasize Prolonged survival is possible even with metastasis, although the longterm diseaserelated mortality rate is highOur objective was to identify the direct targets of ASPSCR1TF and how these targets confer resistance to doxorubicin The human cell lines ASPS1 and FUUR1, as well as mouse tumors driven by expression of ASPSCR1TF were subjected to nuclear fractionation and chromatin immunoprecipitation using antibodies against ASPSCR1 and RNAPol2 Based on morphologic features (nested pattern) and the above IHC results including strong TF expression, ASPS was a strong consideration Although fluorescence in situ hybridization results were positive for TF gene rearrangement, the specific TF/ASPSCR1 rearrangement (X17
Note the t(X;17)(p11;q25) in primary renal ASPSCR1TF tumours is balanced in all known cases Genes involved and Proteins Note Retention of heterozygocity in the tumours of female patients (ie a normal maternal X and a normal paternal X are present, in addition to the Xp11pter involved in the translocation) has been noted in all (n=7 The ASPSCR1/TF fusion replaces the Nterminal portion of TF by the fused ASPSCR1 sequences, while retaining the TF DNAbinding domain, implicating transcriptional deregulation in the pathogenesis of ASPS Heimann et al (01) identified the ASPSCR1 gene, which they called RCC17, partnered with TF in two 5yearold Belgian girls of Cases with ASPSCR1TF, SFPQTF, PRCCTF, and NONOTF gene fusion showed a wide variability in morphologic features, including invasive tubulopapillary pattern simulating collecting duct carcinoma, extensive calcification and ossification, and overlapping and high columnar cells with nuclear grooves mimicking tall cell variant of
ASPSCR1TF alveolar soft part sarcoma Pubmed 17 ASPSCR1TF ASPSCR1TF Adenocarcinoma, Alveolar soft part sarcoma, renal cell carcinoma PubmedIn addition to wildtype TF, ASPSCR1TF fusion transcripts (three type 1 and two type 2 transcripts) were detected in all cases CONCLUSIONS Molecular confirmation of ASPSCR1TF gene fusion is applicable to routinely processed archival and diagnostic tumour samples and aids in the differential diagnosis of ASPS PMID Alveolar soft part sarcoma (ASPS) is a rare malignancy that, since its initial description, remains a neoplasm of uncertain histogenesis The diseasedefining molecular event characterizing the diagnosis of ASPS is the ASPSCR1TF fusion gene Following identification of an index case of ASPS with
The hallmark of ASPS is a chromosomal rearrangement at 17q25 and Xp112 engendering an ASPSCR1TF fusion gene responsible for an aberrant transcription factor presumably enabling pathogenesisThis aberrant chimeric transcription factor retains the Nterminal DNA binding domain encoded by TF while the ASPSCR1 encoded portion probablyTF is also rearranged with ASPSCR1 and other genes in rare forms of renal cell carcinoma, which are most common in children 42 Interestingly, the TFASPSCR1 translocations in the renal cell carcinomas tend to be balanced, whereas the translocation is unbalanced in alveolar soft part sarcoma (Fig 1812A)A fusion partner was identified in 53/60 (%) cases, including 18 SFPQ (PSF), 16 PRCC, 12 ASPSCR1 (ASPL), 6 NONO, and 1 DVL2 We provide the first morphologic description of the NONOTF RCC, which frequently demonstrates subnuclear vacuoles leading to distinctive suprabasal nuclear palisading
The reciprocal 5' TF 3' ASPSCR1 is most often absent ASPSCR1 is fused in frame to TF exon 3 or 4 Abnormal Protein NH2 term ASPSCR1, fused to the C term of TF Oncogenesis might combine the effect of a fusion protein to that of gene(s) dosage Entity primary renal ASPSCR1TF tumour Disease YAP1TFfused hemangioendothelioma is an extremely rare malignant vascular tumor, with only a few dozen cases reported, most of which were single case reports or larger case series that combineSoft Tissue Sarcoma Diagnostic Kit The ASPSCR1TF Fusion/Translocation FISH Probe Kit is designed to detect rearrangements involving the human ASPSCR1 and TF genes located on chromosome bands 17q253 and Xp1123, respectivelyFusion of ASPSCR1 – also known as TUG, ASPL, ASPS, RCC17, UBXD9, UBXN9 or ASPCR1 – with the TF gene – also known as TFEA,
Abstract B54 Enhancer reprogramming by ASPSCR1TF in alveolar soft part sarcoma Miwa Tanaka and Takuro Nakamura Miwa Tanaka The Cancer Inst, Japanese Foundation for Cancer Research, Tokyo, Japan Find this author on Google Scholar Find this author on PubMed Search for this author on this site TF break apart probes in FISH analysis are most effective at detection of the fusion due to multiple partners of the gene ;Disease ASPSCR1/TF renal cell carcinomas harbor the same gene fusion as alveolar soft part sarcoma, but belong to the family of Xp11 translocation RCCXp11 translocation renal cell carcinoma (RCCs) harbor gene fusions involving TF transcription factor The The t(6;11) RCCs harbor a specific MALAT1 (Alpha) TFEB gene fusion TFEB and TF belong to the same MiT subfamily
Aims Alveolar soft part sarcoma (ASPS) is a rare soft tissue tumour with unique morphology and a recurrent, non‐reciprocal translocation der(17)t(X;17)(p112;q25) leading to the fusion of ASPSCR1 (also known as ASPL) to the transcription factor TF Although diagnosis is straightforward in classical cases, tumours with atypical morphological features may be difficult Even our data showed that NONOTF RCC patients had a longer survival than ASPSCR1TF RCC and PRCCTF RCC in a short time followup study However, there was a case at the pT1aM0N0 stageThe most common partner genes in MiT family translocation associated renal cell carcinoma are PRCC and ASPSCR1 (ASPL) (Am J Surg Pathol 16;);
A total of five TF gene fusions (PRCCTF, ASPSCR1TF, SFPQTF, NONOTF, and CLTCTF) and one TFEB gene fusion (MALAT1TFEB) have been identified in RCC tumours and characterized at the mRNA transcript level A multitude of molecular pathways welldescribed in carcinogenesis are regulated in part by TF or TFEB proteins, including ASPSCR1TF is the driving oncogenic feature of this tumor type;PMID 6695 Alveolar soft part sarcoma a bimarker diagnostic strategy using TF immunoassay and ASPLTF fusion transcripts in paraffinembedded tumor tissues Pang LJ, Chang B, Zou H, Qi Y, Jiang JF, Li HA, Hu WH, Chen YZ, Liu CX, Zhang WJ, Li F Diagn Mol Pathol 08 Dec;17 (4) doi /PDM0b013ed68d7
0 件のコメント:
コメントを投稿